

## PARTICIPATING FACULTY

### *Emerging Trends and Formulary Considerations for Atypical Antipsychotics*

This supplement to *The American Journal of Managed Care* contains information on atypical antipsychotics and their cost effectiveness in the treatment of schizophrenia and bipolar disease.

#### *Faculty*

**David J. Harrison, PhD**

Senior Manager  
US Outcomes Research  
Pfizer Inc  
New York, NY

**Robin P. Hertz, PhD**

Senior Director  
Pfizer Inc  
New York, NY

**Amie T. Joyce, MPH**

Senior Research Consultant  
PharMetrics, Inc  
Watertown, MA

**Antony D. Loebel, MD**

Medical Director  
Pfizer Inc  
New York, NY

**Michael B. Lustik, MS**

Statistician  
Science Applications International  
Corporation  
Reston, VA

**Margaret McDonald, PhD**

Director  
Pfizer Inc  
New York, NY

**Daniel A. Ollendorf, MPH**

Vice President  
Analytic & Consulting Services  
PharMetrics, Inc  
Watertown, MA

**George M. Simpson, MD**

Professor of Research in Psychiatry  
Department of Psychiatry and  
the Behavioral Sciences  
LAC + USC Medical Center  
Los Angeles, CA

**Richard C. Surles, PhD**

Senior Vice President and Director  
Comprehensive NeuroScience, Inc  
White Plains, NY

**Alan N. Unger, PhD**

Senior Statistician  
Science Applications International  
Corporation  
Reston, VA

#### *Disclosure Statement*

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following participants have declared the following affiliations with corporate organizations:

■ **David J. Harrison, PhD**

*Employee:*  
Pfizer Inc

■ **Robin P. Hertz, PhD**

*Employee:*  
Pfizer Inc

■ **Amie T. Joyce, MPH**

*Research Support:*  
Pfizer Inc

■ **Antony D. Loebel, MD**

*Employee:*  
Pfizer Inc

■ **Michael B. Lustik, MS**

*Contractor:*  
Pfizer Inc

■ **Margaret McDonald, PhD**

*Employee:*  
Pfizer Inc

■ **Daniel A. Ollendorf, MPH**

*Research Support:*  
Pfizer Inc

■ **George M. Simpson, MD**

*Consultant:*  
Janssen  
Pfizer

*Research Support:*  
AstraZeneca  
GlaxoSmithKline  
Janssen  
Pfizer

■ **Richard C. Surles, PhD**

*Adviser:*  
Eli Lilly and Company

■ **Alan N. Unger, PhD**

*Contractor:*  
Pfizer Inc

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

---

*Emerging Trends and Formulary Considerations  
for Atypical Antipsychotics*

This supplement was funded by **Pfizer Inc.**

*Acknowledgments*

We would like to thank Laura Brasseur and Debbie Godfrey for their contributions to this supplement.

• • •

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.